Drug sales are down. People are opting for generics over more pricey brand names and the FDA approval process has gotten tougher. So what are ailing drug companies to do? According to a cover feature in last weekend's New York Times magazine, pets are the next frontier.
Does Fido stare miserably out the window when you leave for work? Does Spot, like the dog featured in the article, obsessively chase his tail? A dose of Clomicalm, drugmaker Novartis' canine version of Anafranil, a tricyclic antidepressant, may calm his nerves. Eli Lilly's Reconcile, (Prozac for dogs), is also being billed as a remedy for separation anxiety while Pfizer's Anipryl may help absent-minded dogs remember important facts such as the location of their food dish.
Nice to know but I'll pass on the drugs for my excitable, emotional, run-around-like-crazy (but endearing) spaniel.